Current Price Action and Market Context
The stock closed at ₹80.45 on 7 Apr 2026, up from the previous close of ₹79.00, with intraday highs touching ₹81.00 and lows at ₹77.15. This price movement remains significantly below its 52-week high of ₹179.25, indicating persistent weakness over the past year. The 52-week low stands at ₹73.63, suggesting the stock is trading closer to its lower range, which may be a concern for investors seeking stability.
Comparatively, Themis Medicare’s returns have been volatile and largely underperforming the benchmark Sensex over recent periods. While the stock posted a strong 1-week return of 22.13% against Sensex’s 3.00%, longer-term returns tell a different story. Year-to-date, the stock is down 20.07% compared to Sensex’s 13.04% decline, and over one year, it has plunged 42.62% versus a marginal 1.67% fall in the Sensex. Even over three years, Themis Medicare has declined 37.23%, while the Sensex gained 23.86%. However, the stock’s five-year return of 162.05% outpaces the Sensex’s 50.62%, reflecting some historical resilience despite recent setbacks.
Technical Indicator Analysis: MACD, RSI, and Moving Averages
The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture. On a weekly basis, the MACD is mildly bullish, signalling some positive momentum building in the short term. However, the monthly MACD remains bearish, indicating that the longer-term trend is still under pressure. This divergence suggests that while short-term traders may find some opportunities, the broader trend remains cautious.
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This lack of momentum in RSI implies that the stock is neither overbought nor oversold, which may lead to sideways price action unless other catalysts emerge.
Moving averages on the daily chart continue to be bearish, reinforcing the prevailing downtrend in the near term. The stock remains below key moving averages, which often act as resistance levels, limiting upside potential until a decisive breakout occurs.
Additional Technical Signals and Trend Assessments
Bollinger Bands on weekly and monthly timeframes are mildly bearish, indicating that price volatility is skewed towards the downside. The stock price is closer to the lower band, which may suggest some oversold conditions but also highlights the risk of further declines if selling pressure intensifies.
The Know Sure Thing (KST) oscillator echoes the MACD’s mixed signals, showing mild bullishness on the weekly chart but bearishness on the monthly chart. This reinforces the notion of short-term strength amid longer-term weakness.
Dow Theory analysis aligns with these findings, with a mildly bullish weekly trend but no clear monthly trend established. This lack of a definitive monthly trend adds to the uncertainty surrounding the stock’s medium-term direction.
On-Balance Volume (OBV) indicators on both weekly and monthly charts show no clear trend, suggesting that volume is not confirming price movements decisively. This absence of volume support may limit the sustainability of any short-term rallies.
Transformation in full progress! This Micro Cap from Auto Ancillary just achieved sustainable profitability after tough times. Be early to witness this powerful comeback story!
- - Sustainable profitability reached
- - Post-turnaround strength
- - Comeback story unfolding
Mojo Score and Rating Update
Themis Medicare currently holds a Mojo Score of 31.0, categorised as a 'Sell' rating, an upgrade from its previous 'Strong Sell' grade as of 6 Apr 2026. This slight improvement reflects the recent technical momentum shift from bearish to mildly bearish, but the overall outlook remains cautious. The company is classified as a micro-cap within the Pharmaceuticals & Biotechnology sector, which inherently carries higher volatility and risk.
Investors should note that despite the upgrade, the Mojo Grade remains firmly in the sell territory, signalling that the stock has yet to demonstrate convincing strength or a sustainable turnaround. The mixed technical signals and subdued volume trends further reinforce the need for prudence.
Comparative Performance and Sector Context
Within the Pharmaceuticals & Biotechnology sector, Themis Medicare’s performance has lagged behind broader market indices and peers. While the sector has seen pockets of strength driven by innovation and regulatory approvals, Themis Medicare’s subdued returns and technical challenges highlight company-specific hurdles. The stock’s 10-year return of 121.50% trails the Sensex’s 197.61%, underscoring the need for strategic reassessment by investors.
Given the sector’s dynamic nature, investors may consider monitoring peer companies with stronger technical profiles and more robust fundamentals for potential portfolio rebalancing.
Holding Themis Medicare Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaway and Outlook
Themis Medicare’s recent technical momentum shift to mildly bearish from bearish, combined with a modest daily price gain, suggests tentative signs of stabilisation. However, the predominance of bearish signals on longer-term indicators such as monthly MACD, moving averages, and Bollinger Bands, alongside neutral RSI and volume trends, indicates that the stock remains vulnerable to downside risks.
Investors should approach Themis Medicare with caution, considering the stock’s micro-cap status and sector volatility. The upgrade from Strong Sell to Sell rating reflects some improvement but does not yet warrant a bullish stance. Monitoring for confirmation of sustained technical strength, such as a break above key moving averages and improved volume support, will be critical before considering accumulation.
Given the stock’s underperformance relative to the Sensex and sector peers, portfolio diversification and peer comparison remain prudent strategies. The pharmaceutical sector’s evolving landscape demands careful stock selection, favouring companies with clearer technical and fundamental momentum.
Summary of Key Technical Metrics:
- Current Price: ₹80.45 (7 Apr 2026)
- Day Change: +1.84%
- 52-Week Range: ₹73.63 - ₹179.25
- Technical Trend: Mildly Bearish (from Bearish)
- MACD: Weekly Mildly Bullish, Monthly Bearish
- RSI: No Signal (Weekly & Monthly)
- Bollinger Bands: Mildly Bearish (Weekly & Monthly)
- Moving Averages: Daily Bearish
- KST: Weekly Mildly Bullish, Monthly Bearish
- Dow Theory: Weekly Mildly Bullish, Monthly No Trend
- OBV: No Trend (Weekly & Monthly)
- Mojo Score: 31.0 (Sell, upgraded from Strong Sell)
Conclusion
Themis Medicare Ltd’s technical landscape is characterised by a delicate balance between short-term bullish signals and longer-term bearish pressures. While the recent upgrade in rating and mild momentum improvements offer some optimism, the stock’s overall technical and fundamental profile suggests that investors should remain circumspect. Continued monitoring of technical indicators and sector developments will be essential to gauge any meaningful turnaround in this micro-cap pharmaceutical stock.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
